Non-aromatic difluoro analogues of resorcylic acid lactones

1. A compound having the structure:

or a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is not a prodrug or a metabolite; wherein

V W is CH 2 CH 2 , CH═CH, or

Y Z is CH 2 CH 2 ,

 CH═CH, or

R 12 is hydrogen, hydroxyl, or methyl;

R 13 , R 15 , and R 17 may each independently be present or absent and if present R 13 , R 15 , and R 17 are each independently hydrogen or hydroxyl;

R 14 and R 16 are each independently hydrogen or hydroxyl;

wherein R 12 and R 13 , when taken together, may optionally be O

wherein R 13 and R 14 , when taken together, may optionally be

wherein R 14 and R 16 , when taken together, may optionally be

and

R 18 is C 1 -C 20 alkyl, hydrogen, methyl, or

2. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is not a prodrug or a metabolite.

3. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is not a prodrug or a metabolite.

4. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is not a prodrug or a metabolite.

5. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is not a prodrug or a metabolite.

6. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is not a prodrug or a metabolite.

7. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is not a prodrug or a metabolite.

8. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is not a prodrug or a metabolite.

9. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and a compound of claim 1 .

10. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and a compound of claim 2 .

11. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and a compound of claim 3 .

12. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and a compound of claim 4 .

13. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and a compound of claim 5 .

14. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and a compound of claim 6 .

15. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and a compound of claim 7 .

16. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or diluent; and a compound of claim 8 .

17. A method for treating breast cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, leukemia, or ovarian cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , and a pharmaceutically acceptable carrier or diluent.

18. A method for treating breast cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, leukemia, or ovarian cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 2 , and a pharmaceutically acceptable carrier or diluent.

19. A method for treating breast cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, leukemia, or ovarian cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 3 , and a pharmaceutically acceptable carrier or diluent.

20. A method for treating breast cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, leukemia, or ovarian cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 4 , and a pharmaceutically acceptable carrier or diluent.

21. A method for treating breast cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, leukemia, or ovarian cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 5 , and a pharmaceutically acceptable carrier or diluent.

22. A method for treating breast cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, leukemia, or ovarian cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 6 , and a pharmaceutically acceptable carrier or diluent.

23. A method for treating breast cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, leukemia, or ovarian cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 7 , and a pharmaceutically acceptable carrier or diluent.

24. A method for treating breast cancer, colon cancer, hepatocellular carcinoma, renal cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, leukemia, or ovarian cancer comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 8 , and a pharmaceutically acceptable carrier or diluent.